Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer.
Sampathkumar Y, Zakaria Z, O'Connell K, Bhimani J, Blinder VS, Burganowski R, Ergas IJ, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Monroy-Iglesias MJ, Nakata KG, Persaud S, Roh JM, Tabatabai S, Valice E, Wang P, Bandera EV, Aiello Bowles EJ, Kushi LH, Kantor ED.
Sampathkumar Y, et al. Among authors: laurent ca.
J Natl Cancer Inst. 2026 Mar 4:djag063. doi: 10.1093/jnci/djag063. Online ahead of print.
J Natl Cancer Inst. 2026.
PMID: 41782330
Free PMC article.